Metagenomi Therapeutics, Inc. Operating Income
Metagenomi Therapeutics, Inc. (MGX) reported Operating Income of -$28.77 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-10
- Metagenomi Therapeutics, Inc. operating income (loss) for the quarter ending 2026-06-30 was -$28.77M.
- Metagenomi Therapeutics, Inc. operating income (loss) for the quarter ending 2026-03-31 was -$24.59M.
- Metagenomi Therapeutics, Inc. operating income (loss) for the quarter ending 2025-12-31 was -$24.37M.
- Metagenomi Therapeutics, Inc. operating income (loss) for the quarter ending 2025-09-30 was -$22.84M.
- Metagenomi Therapeutics, Inc. operating income (loss) for fiscal 2025 was -$96.01M.
- Metagenomi Therapeutics, Inc. operating income (loss) for fiscal 2024 was -$88.90M.
- Metagenomi Therapeutics, Inc. operating income (loss) for fiscal 2023 was -$78.49M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$28.77M 10-Q · filed 2026-08-10 | -$53.36M 10-Q · filed 2026-08-10 | -$77.73M derived: sum of 3 quarters · filed 2026-08-10 | -$100.57M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$24.59M 10-Q · filed 2026-05-11 | -$48.95M derived: sum of 2 quarters · filed 2026-05-11 | -$71.79M derived: sum of 3 quarters · filed 2026-05-11 | -$92.78M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$24.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$47.21M derived: sum of 2 quarters · filed 2026-03-05 | -$68.19M derived: sum of 3 quarters · filed 2026-08-10 | -$96.01M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$22.84M 10-Q · filed 2025-11-12 | -$43.83M derived: sum of 2 quarters · filed 2026-08-10 | -$71.65M 10-Q · filed 2025-11-12 | -$92.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$20.99M 10-Q · filed 2026-08-10 | -$48.81M 10-Q · filed 2026-08-10 | -$69.43M derived: sum of 3 quarters · filed 2026-08-10 | -$91.81M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$27.82M 10-Q · filed 2026-05-11 | -$48.44M derived: sum of 2 quarters · filed 2026-05-11 | -$70.83M derived: sum of 3 quarters · filed 2026-05-11 | -$87.69M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | -$20.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$43.01M derived: sum of 2 quarters · filed 2026-03-05 | -$59.87M derived: sum of 3 quarters · filed 2026-03-05 | -$88.90M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$22.38M 10-Q · filed 2025-11-12 | -$39.25M derived: sum of 2 quarters · filed 2025-11-12 | -$68.28M 10-Q · filed 2025-11-12 | -$88.47M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$16.86M 10-Q · filed 2025-08-12 | -$45.90M 10-Q · filed 2025-08-12 | -$66.09M derived: sum of 3 quarters · filed 2025-08-12 | -$88.49M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$29.03M 10-Q · filed 2025-05-13 | -$49.23M derived: sum of 2 quarters · filed 2025-05-13 | -$71.62M derived: sum of 3 quarters · filed 2025-05-13 | -$89.59M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$20.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$42.59M derived: sum of 2 quarters · filed 2025-03-17 | -$60.55M derived: sum of 3 quarters · filed 2025-03-17 | -$78.49M 10-K · filed 2025-03-17 |
| 2023-09-30 | -$22.39M 10-Q · filed 2024-11-13 | -$40.36M derived: sum of 2 quarters · filed 2024-11-13 | -$58.30M 10-Q · filed 2024-11-13 | |
| 2023-06-30 | -$17.96M 10-Q · filed 2024-08-14 | -$35.90M 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | -$17.94M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |